Berlin - Delayed Quote EUR

Travere Therapeutics Inc (17R.BE)

16.40

-0.80

(-4.65%)

At close: December 13 at 9:52:06 PM GMT+1

Travere Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in December: 7th Annual Evercore HealthCONx ConferenceTuesday, December 3, 2024, at 10:00 a.m. ET Citi 2024 Global Healthcare ConferenceWednesday, December 4, 2024, at 2:30 p.m. ET Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentati

GlobeNewswire 19 days ago

TVTX
Exploring Three High Growth Tech Stocks in the United States

The United States market has been flat in the last week yet it is up 32% over the past year with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks that align with these robust market conditions can be crucial for investors looking to capitalize on potential opportunities.

Simply Wall St. 29 days ago

RIGL

ADSK

TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 24,400 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan

GlobeNewswire last month

TVTX
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the completion of its previously announced underwritten public offering of 8,984,375 shares of its common stock at a price to the public of $16.00 per share, including 1,171,875 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares. All of the shares were sold by Travere. Including the option exercise, the aggregate gross proceeds from the offeri

GlobeNewswire last month

TVTX
Travere Therapeutics Announces Pricing of Public Offering of Common Stock

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of $16.00 per share. All of the shares are being sold by Travere. The gross proceeds from the offering are expected to be $125.0 million, before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close on November 12, 2024, subject

GlobeNewswire last month

TVTX
Travere Therapeutics Announces Proposed Public Offering of Common Stock

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, shares of its common stock. All of the shares are being offered by Travere. In addition, Travere intends to grant the underwriters for the offering a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. There can be no a

GlobeNewswire last month

TVTX
Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Travere Therapeutics ( NASDAQ:TVTX ) Third Quarter 2024 Results Key Financial Results Revenue: US$62.9m (up 70% from 3Q...

Simply Wall St. last month

TVTX
Travere Therapeutics Reports Third Quarter 2024 Financial Results

FILSPARI® (sparsentan) received full FDA approval as the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN Type C meeting scheduled with FDA to discuss potential sNDA submission for FILSPARI in FSGS sNDA requesting modification of liver monitoring for FILSPARI submitted to FDA Net product sales of FILSPARI totaled $35.6 million for the third quarter of 2024; 505 new PSFs received in the period Total revenue for the third quarter of 2024 was $62.9 milli

GlobeNewswire last month

TVTX
Travere presents data reinforcing clinical benefit of FILSPARI in IgAN

Travere Therapeutics (TVTX) presented new data further demonstrating the clinical benefit of FILSPARI in IgA nephropathy and reinforcing its potential in focal segmental glomerulosclerosis at the American Society of Nephrology Kidney Week 2024. Key findings from the PROTECT study subgroup analysis of patients with proteinuria above and below 1 g/g: FILSPARI delivered superior proteinuria reduction, and complete proteinuria remission earlier and more frequently compared to irbesartan regardless o

TipRanks last month

TVTX
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024

Nearly 60% of patients with IgAN in the SPARTAN Study achieved complete remission when using FILSPARI as first-line treatment SPARTACUS Study, PROTECT open-label extension, and real-world evidence presentations highlight initial safety and efficacy data of FILSPARI in combination treatment in IgAN Late-breaking presentation demonstrates sparsentan delivered rapid and sustained proteinuria reduction, and long-term kidney health benefits in a subset of patients with genetic, often treatment resist

GlobeNewswire last month

TVTX
Travere Therapeutics to Report Third Quarter 2024 Financial Results

SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2024 financial results on Thursday, October 31, 2024, before the open of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 8:30 a.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere’s website at ir.travere.com/events-presenta

GlobeNewswire last month

TVTX
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT TrialSAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) and CSL Vifor today announced that Swissmedic has granted temporary marketing authorization for FILSPARI for the treatment of adults with primary IgA nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). “FILSPARI targe

GlobeNewswire last month

TVTX

CMXHF

CSLLY
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Swissmedic has granted temporary marketing authorization for FILSPARI for the treatment of adults with primary IgA nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g).

CNW Group last month

CMXHF

CSLLY

TVTX
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024

Data presentations highlight the results for FILSPARI® (sparsentan), the only approved kidney-targeted medicine for IgA nephropathy, when used as a first-line treatment, and in combination with other therapies Late-breaking presentation details outcomes of sparsentan’s effect in a subgroup of high-risk patients with genetic focal segmental glomerulosclerosis SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present 11 ab

GlobeNewswire last month

TVTX
Travere Therapeutics Inc (TVTX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Travere Therapeutics Inc (TVTX) reports a 77% increase in net product sales, driven by FILSPARI's performance, while navigating regulatory and competitive hurdles.

GuruFocus.com 2 months ago

TVTX
Travere Therapeutics, Inc. (TVTX) Increases R&D Investments Amidst Rising Product Sales

We recently published a list of 10 Best Biotech Stocks To Buy Under $20. In this article, we are going to take a look at where Travere Therapeutics, Inc. (NASDAQ:TVTX) stands against the other best biotech stocks to buy under $20. The biotechnology industry is experiencing rapid growth, driven by increasing demand for innovative treatments, […]

Insider Monkey 2 months ago

TVTX
Exploring 3 High Growth Tech Stocks in the United States

The United States market has remained flat over the last week but is up 32% over the past year with earnings forecast to grow by 15% annually. In this environment, identifying high growth tech stocks often involves looking for companies with innovative products and strong potential for revenue expansion.

Simply Wall St. 2 months ago

AIOT

TVTX

DV
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up

Company to host conference call today at 4:30 p.m. ETSAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU). The voluntary enrollment pause enables the Company to work to address necessary process improvements in manufacturing scale-up to support commercial scale manufacturing as well as full enrollment in the

GlobeNewswire 2 months ago

TVTX
Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present at the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024, at 9:45 a.m. ET. A live webcast will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentations, and a replay will be available for up to 30 days following the event. About Travere Therapeutics At Travere Therapeutics, we are in rare for life

GlobeNewswire 3 months ago

TVTX
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

FILSPARI (sparsentan) FILSPARI (sparsentan) FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term durable benefit on proteinuria and kidney function preservation that accrued over two years Conversion to full approval based on results from the PROTECT Study, where FILSPARI delivered superior long-term kidney function preservation compared to the active comparator irbesartan in the o

GlobeNewswire 3 months ago

TVTX

Performance Overview

Return	17R.BE	S&P 500
YTD	+94.08%	+26.86%
1-Year	+100.00%	+30.31%
3-Year	-31.67%	+28.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Travere Therapeutics Inc (17R.BE)

Travere Therapeutics to Present at Upcoming Investor Conferences

Exploring Three High Growth Tech Stocks in the United States

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

Travere Therapeutics Announces Pricing of Public Offering of Common Stock

Travere Therapeutics Announces Proposed Public Offering of Common Stock

Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Travere Therapeutics Reports Third Quarter 2024 Financial Results

Travere presents data reinforcing clinical benefit of FILSPARI in IgAN

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024

Travere Therapeutics to Report Third Quarter 2024 Financial Results

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024

Travere Therapeutics Inc (TVTX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Travere Therapeutics, Inc. (TVTX) Increases R&D Investments Amidst Rising Product Sales

Exploring 3 High Growth Tech Stocks in the United States

Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up

Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

Performance Overview